Mónica Inês1, Teresa Coelho2,3, Isabel Conceição4,5, Filipa Duarte-Ramos6, Mamede de Carvalho4,5, João Costa4,7. 1. Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugalmonica.s.ines@gmail.com. 2. Andrade's Center for Familial Amyloidosis, Porto, Portugal. 3. Department of Neurosciences, Hospital de Santo António, Porto, Portugal. 4. Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal. 5. Department of Neurosciences and Mental Health, Hospital de Santa Maria, Lisboa, Portugal. 6. Department of Social Pharmacy, Faculty of Pharmacy, University of Lisboa, Lisboa, Portugal. 7. Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.
Abstract
BACKGROUND: Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a rare, hereditary, progressive and neurodegenerative disease. We aimed to study -TTR-FAP epidemiology in Portugal. METHODS: National, observational, prospective and retrospective, case identification of adults with TTR-FAP. Countrywide patient multiple identification sources included reference centers registries and centralized medical electronic prescription database. Crude rates were reported per 100,000 adult inhabitants. RESULTS: Over 2010-2016 period, mean incidence rates was 0.87/100,000 (95% CI 0.68-1.10) corresponding to 71 new patients yearly, that has decreased 31% in the last 7 years. The proportion of late-onset cases (age ≥50 years) among incident cases was 28.7%. Estimated crude 2016 prevalence was 22.93/100,000 adult inhabitants (95% CI 21.90-23.99) corresponding to 1,865 TTR-FAP individuals in Portugal (45.8% male; mean age: 52.3 ± 15.4 years). In 2016, the Portuguese region with the highest TTR-FAP prevalence shows a 16% prevalence increase over the last 25 years. CONCLUSIONS: In Portugal, TTR-FAP affects both genders and mainly young adults. TTR-FAP incidence appears to be decreasing while prevalence is increasing. In comparison to previous studies, there is an increased representativeness of late-onset patients. This epidemiological setting poses future and complex challenges for the social and healthcare system, strengthening the relevance of regular epidemiologic surveillance.
BACKGROUND:Transthyretin-associated familial amyloid polyneuropathy (TTR-FAP) is a rare, hereditary, progressive and neurodegenerative disease. We aimed to study -TTR-FAP epidemiology in Portugal. METHODS: National, observational, prospective and retrospective, case identification of adults with TTR-FAP. Countrywide patient multiple identification sources included reference centers registries and centralized medical electronic prescription database. Crude rates were reported per 100,000 adult inhabitants. RESULTS: Over 2010-2016 period, mean incidence rates was 0.87/100,000 (95% CI 0.68-1.10) corresponding to 71 new patients yearly, that has decreased 31% in the last 7 years. The proportion of late-onset cases (age ≥50 years) among incident cases was 28.7%. Estimated crude 2016 prevalence was 22.93/100,000 adult inhabitants (95% CI 21.90-23.99) corresponding to 1,865 TTR-FAP individuals in Portugal (45.8% male; mean age: 52.3 ± 15.4 years). In 2016, the Portuguese region with the highest TTR-FAP prevalence shows a 16% prevalence increase over the last 25 years. CONCLUSIONS: In Portugal, TTR-FAP affects both genders and mainly young adults. TTR-FAP incidence appears to be decreasing while prevalence is increasing. In comparison to previous studies, there is an increased representativeness of late-onset patients. This epidemiological setting poses future and complex challenges for the social and healthcare system, strengthening the relevance of regular epidemiologic surveillance.
Authors: Antonia Carroll; P James Dyck; Mamede de Carvalho; Marina Kennerson; Mary M Reilly; Matthew C Kiernan; Steve Vucic Journal: J Neurol Neurosurg Psychiatry Date: 2022-03-07 Impact factor: 13.654
Authors: Maria do Carmo Vilas-Boas; Pedro Filipe Pereira Fonseca; Inês Martins Sousa; Márcio Neves Cardoso; João Paulo Silva Cunha; Teresa Coelho Journal: J Clin Med Date: 2022-07-07 Impact factor: 4.964
Authors: Mariana Amorim; Susana Silva; Helena Machado; Elisa Leão Teles; Maria João Baptista; Tiago Maia; Ngozi Nwebonyi; Cláudia de Freitas Journal: Int J Environ Res Public Health Date: 2022-07-19 Impact factor: 4.614
Authors: Maria do Carmo Vilas-Boas; Ana Patrícia Rocha; Márcio Neves Cardoso; José Maria Fernandes; Teresa Coelho; João Paulo Silva Cunha Journal: Front Neurol Date: 2020-11-23 Impact factor: 4.086